The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Spruce Biosciences has put out new shoots, snapping up rights to a former BioMarin rare disease candidate and outlining plans ...

BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The South San Francisco biotech has acquired rights to tralesinidase alfa, an enzyme replacement therapy (ERT) for the ...

Wall Street expects a year-over-year increase in earnings on higher revenues when BioMarin Pharmaceutical (BMRN) reports results for the quarter ended March 2025. While this widely-known consensus ...

From Washington to Wall Street, it's a crazy time for biotech. But as Ultragenyx Pharmaceutical Inc. celebrates its 15th ...

ASND thrives amid market volatility, with Yorvipath's strong potential & strategic focus on rare diseases. Click here to find ...

Q1 2023 Earnings Call Transcript April 15, 2025 Spruce Biosciences, Inc. misses on earnings expectations. Reported EPS is $-0 ...

BioMarin's has signed the first contract with an insurer in Germany for Roctavian, its recently approved gene therapy for haemophilia A, as it tests out its outcomes-based agreement (OBA ...

Sequentify is offering research grants to accelerate high-impact genomic studies through its uniquely fast, easy-to-use, and scalable targeted library preparation technology. Designed to enable the ...